India Pharma Outlook Team | Monday, 29 June 2026
Haryana is all set to pass a policy for building pharma hubs. This initiative is rolled out under the Pharmaceuticals and Medical Devices Manufacturing Policy, 2026.
This aims to create about 20,000 job opportunities for the next five years along with building more medical hubs, availing affordable domestic medicines, medical devices and high-value health care.
This project aims to capitalise on the growing Indian Pharma Industry, as well as to reduce its dependence on foreign markets for high-value critical drugs. The Industries and Commerce Secretary, Amit Aggarwal, quotes that, “this project aims to turn Haryana into a global competitive market hub.”
The Indian Pharma market is growing rapidly, as new research and developments have gained value and popularity over time. Drug discoveries and approvals have lately introduced Indian Pharma into various global markets.
This ultimately demands the need for further manufacturing hubs in the country. And Haryana has taken the step to do so. This policy also aims to increase the competitiveness of India’s healthcare manufacturing globally.
As per reports, India supplies over 20 per cent of global generics and 60 per cent of vaccines globally, but still heavily depends on foreign imports for advanced medical devices and other high-value generics. Therefore, the policy aims to fill this gap and attract investments of over 10,000 crore.
This policy is a game changer, because currently no state has such a policy, which benefits both the state infrastructure developments and the consequent effects in the Indian market. AiMeD has announced that “this is possibly the most progressive framework by any state in India.”
Also Read: The Evolving Role of India as a Talent Hub for Healthcare R&D
The Policy currently introduced by the Haryana government attracts 10,000 crore investment and 20,000 job opportunities that will foster innovation in the pharmaceutical as well as medical devices sector. The policy reportedly welcomes incentives with CAPEX support of 30 per cent.
Similarly, OPEX support up to 80 per cent is also, the policy arrives at a time when the current Indian Pharma is of the value USD 50 billion. This is estimated to grow to USD 150 billion by 2030. Further policy plans for incentives on research and development, innovation, and certification on international quality.
Rajiv Nath, Forum Coordinator, AiMeD, said that this policy will truly unlock India’s healthcare manufacturing potential, reducing the compliance burden. He further urged the state and central government to provide a three-year compliance holiday for green-field investments.
Therefore, the arrival of this policy creates hope for better developments in the Indian pharma market, expected to improve the ease of doing business and promoting the oversea exports, thereby reducing India’s dependence on imports. Creating better opportunities to be a certified leader in the global pharma market.
.jpg)
